Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
Anteris Technologies (NASDAQ/ASX: AVR), a structural heart company developing the DurAVR THV biomimetic heart valve, has announced its participation in two major healthcare investor conferences.
CEO Wayne Paterson will present at both the 45th Annual TD Cowen Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference. Additionally, Chief Medical Officer Dr. Chris Meduri will participate as an expert panelist in the Structural Heart-TAVR panel discussion, which will be moderated by Joshua Jennings.
Investors can access the conference fireside chat webcasts through the Investor Center section on the Anteris website, where recordings will remain available for up to 90 days.
Anteris Technologies (NASDAQ/ASX: AVR), un'azienda specializzata nel cuore strutturale che sviluppa la valvola cardiaca biomimetica DurAVR THV, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario.
Il CEO Wayne Paterson presenterà sia alla 45ª Conferenza Annuale TD Cowen sulla Salute che alla 27ª Conferenza Annuale Globale sulla Salute di Barclays. Inoltre, il Chief Medical Officer Dr. Chris Meduri parteciperà come esperto nel panel di discussione sul Cuore Strutturale-TAVR, che sarà moderato da Joshua Jennings.
Gli investitori possono accedere alle registrazioni delle conversazioni delle conferenze attraverso la sezione Investor Center sul sito web di Anteris, dove le registrazioni rimarranno disponibili per un massimo di 90 giorni.
Anteris Technologies (NASDAQ/ASX: AVR), una empresa de tecnología cardíaca estructural que desarrolla la válvula cardíaca biomimética DurAVR THV, ha anunciado su participación en dos importantes conferencias de inversores en el sector de la salud.
El CEO Wayne Paterson presentará en la 45ª Conferencia Anual de Salud TD Cowen y en la 27ª Conferencia Global Anual de Salud de Barclays. Además, el Director Médico Dr. Chris Meduri participará como panelista experto en la discusión del panel sobre Corazón Estructural-TAVR, que será moderada por Joshua Jennings.
Los inversores pueden acceder a las grabaciones de las charlas de la conferencia a través de la sección Investor Center en el sitio web de Anteris, donde las grabaciones estarán disponibles durante un máximo de 90 días.
안테리스 테크놀로지스 (NASDAQ/ASX: AVR)는 DurAVR THV 생체모방 심장판막을 개발하는 구조적 심장 회사로, 두 개의 주요 의료 투자자 회의에 참여한다고 발표했습니다.
CEO 웨인 패터슨은 제45회 TD 코웬 의료 회의와 바클레이즈 제27회 글로벌 의료 회의에서 발표할 예정입니다. 또한, 최고 의료 책임자 크리스 메두리 박사는 조슈아 제닝스가 진행하는 구조적 심장-TAVR 패널 토론에 전문가 패널리스트로 참여할 것입니다.
투자자들은 안테리스 웹사이트의 투자자 센터 섹션을 통해 회의의 화상 채팅 웹캐스트에 접근할 수 있으며, 녹화된 내용은 최대 90일 동안 이용 가능합니다.
Anteris Technologies (NASDAQ/ASX: AVR), une entreprise spécialisée dans les technologies cardiaques structurelles développant la valve cardiaque biomimétique DurAVR THV, a annoncé sa participation à deux grandes conférences pour investisseurs dans le domaine de la santé.
Le PDG Wayne Paterson fera une présentation lors de la 45e Conférence Annuelle TD Cowen sur la Santé et de la 27e Conférence Annuelle Mondiale de la Santé de Barclays. De plus, le Directeur Médical Dr. Chris Meduri participera en tant que panéliste expert à la discussion du panel sur le Cœur Structurel-TAVR, qui sera modérée par Joshua Jennings.
Les investisseurs peuvent accéder aux enregistrements des discussions des conférences via la section Investor Center sur le site web d'Anteris, où les enregistrements resteront disponibles pendant 90 jours maximum.
Anteris Technologies (NASDAQ/ASX: AVR), ein Unternehmen für strukturelle Herztechnologie, das das biomimetische Herzklappenprodukt DurAVR THV entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitswesen angekündigt.
CEO Wayne Paterson wird sowohl auf der 45. jährlichen TD Cowen Gesundheitskonferenz als auch auf der 27. jährlichen globalen Gesundheitskonferenz von Barclays präsentieren. Außerdem wird Chief Medical Officer Dr. Chris Meduri als Fachexperte an der Paneldiskussion über strukturelle Herzen-TAVR teilnehmen, die von Joshua Jennings moderiert wird.
Investoren können über den Investor Center-Bereich der Anteris-Website auf die Aufzeichnungen der Konferenzgespräche zugreifen, die bis zu 90 Tage lang verfügbar bleiben.
- None.
- None.
MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Anteris® Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a structural heart company developing DurAVR® THV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference.
The details of each conference and how to access them are as follows:
| TD Cowen 45th Annual Healthcare Conference | |||
| Date: | Wednesday, March 5th, 2025 (US time) | ||
| Format: | Fireside chat with analyst, Joshua Jennings, and 1x1 meetings | ||
| Time: | 9:10-9:40AM (US EST) | ||
| Room: | Provincetown, 4th Floor | ||
| Location: | Marriott Copley Plaza, Boston, MA | ||
| Webcast link: | https://wsw.com/webcast/cowen177/avr.ax/2275728 | ||
In addition, Anteris Chief Medical Officer, Dr. Chris Meduri, MD, MPH, will be one of the expert panelists on the Structural Heart-TAVR panel discussion moderated by Joshua Jennings.
| Date: | Wednesday, March 5th, 2025 (US time) | ||
| Format: | Panel discussion | ||
| Time: | 3:10-4:10PM (US EST) | ||
| Room: | Salon D, 4th Floor | ||
| Location: | Marriott Copley Plaza, Boston, MA |
| Barclays 27th Annual Global Healthcare Conference | |||
| Date: | Tuesday, March 11th, 2025 (US time) | ||
| Format: | Fireside chat with analyst, Matt Miksic, and 1x1 meetings | ||
| Time: | 9:00-9:25AM (US EST) | ||
| Room: | Americana 3 (Track 3) | ||
| Location: | Loews Miami Beach, Miami, FL | ||
| Webcast link: | https://cc.webcasts.com/barc002/031125a_js/?entity=80_U2ODGGH | ||
The webcasts of the TD Cowen and Barclays fireside chats can be accessed by visiting the Investor Center section of the Company’s website at https://anteristech.com/investors/investor-presentations.html. A replay of the webcast will be archived for up to 90 days.
About Anteris
Anteris® Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ registration statement filed on 10 December 2024 with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, neither ATL or Anteris assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
Authorisation and Additional information
This announcement was authorised for release on the ASX by the Disclosure Committee of Anteris.
| For more information: | |||
| Investor Relations (Global) | Investor Relations (US) | ||
| investors@anteristech.com | mchatterjee@bplifescience.com | ||
| Debbie Ormsby | Malini Chatterjee, Ph.D. | ||
| Anteris Technologies Global Corp. | Blueprint Life Science Group | ||
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 | ||
| Website | www.anteristech.com | ||
| X | @AnterisTech | ||
| www.facebook.com/anteristech | |||
| https://www.linkedin.com/company/anteristech |
FAQ
What upcoming investor conferences will Anteris (AVR) present at in 2025?
Who will represent Anteris (AVR) at the upcoming healthcare conferences?
How can investors access Anteris (AVR) conference presentations?
How long will Anteris (AVR) conference webcasts be available for replay?
